Compare RBKB & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBKB | AGEN |
|---|---|---|
| Founded | 1860 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.0M | 126.2M |
| IPO Year | 2019 | 2000 |
| Metric | RBKB | AGEN |
|---|---|---|
| Price | $11.96 | $4.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 7.0K | ★ 738.6K |
| Earning Date | 01-29-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | $45,306,000.00 | ★ $106,829,000.00 |
| Revenue This Year | N/A | $23.68 |
| Revenue Next Year | N/A | $23.17 |
| P/E Ratio | $26.17 | ★ N/A |
| Revenue Growth | ★ 54.93 | N/A |
| 52 Week Low | $9.31 | $1.38 |
| 52 Week High | $13.99 | $7.34 |
| Indicator | RBKB | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 46.99 | 74.42 |
| Support Level | $11.56 | $3.01 |
| Resistance Level | $12.10 | $4.00 |
| Average True Range (ATR) | 0.32 | 0.26 |
| MACD | -0.10 | 0.18 |
| Stochastic Oscillator | 18.68 | 87.34 |
Rhinebeck Bancorp Inc is the holding company for Rhinebeck Bank which provides a full range of banking and financial services to consumer and commercial customers. Financial services, including investment advisory and financial product sales, are offered through a division of the Bank doing business as Rhinebeck Asset Management (RAM). The Bank's primary business activity is accepting deposits from the general public and using those funds to originate indirect automobile loans (automobile loans referred by automobile dealerships), commercial real estate loans (which include multi-family real estate loans and commercial construction loans), commercial business loans and one-to four-family residential real estate loans, and to purchase investment securities.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).